




RealRate

PHARMACEUTICAL 2022

Dare Bioscience Inc.
Rank 369 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



RealRate

PHARMACEUTICAL 2022

Dare Bioscience Inc.
Rank 369 of 475



The relative strengths and weaknesses of Dare Bioscience Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dare Bioscience Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 50% points. The greatest weakness of Dare Bioscience Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 188% points.

The company's Economic Capital Ratio, given in the ranking table, is -315%, being 38% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	55,296
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,053
Liabilities, Non-Current	1,000
Other Assets	485
Other Compr. Net Income	-64
Other Expenses	100
Other Liabilities	0
Other Net Income	372
Property and Equipment	26
Research and Development	30,618
Revenues	0
Selling, General and Administrative Expense	8,351

Output Variable	Value in 1000 USD
Assets	55,807
Liabilities	17,053
Expenses	39,069
Stockholders Equity	38,754
Net Income	-38,696
Comprehensive Net Income	-38,728
Economic Capital Ratio	-315%



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai